RPG Life Sciences · NSE: RPGLIFE · BSE: 532983
Q3 FY26 results · Oct–Dec 2025
RPG Life Sciences reported revenue from operations of ₹180.03 crore and net profit of ₹22.13 crore for Q3 FY26 (Oct–Dec 2025), on a consolidated basis.
| Item | Q3 FY26 | Q3 FY25 | YoY | Q2 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 180.03 | — | — | — | — |
| Other income | 3.41 | — | — | — | — |
| Total income | 183.44 | — | — | — | — |
| Profit before tax | 29.12 | — | — | — | — |
| Net profit for the period | 22.13 | — | — | — | — |
| EPS, basic (₹) | 13.38 | — | — | — | — |
| Net margin (%) | 12.3 | — | — |
| Item | Q3 FY26 | Q3 FY25 | YoY | Q2 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 180.03 | 172.71 | +4.2% | 181.68 | −0.9% |
| Other income | 3.41 | 3.31 | +3.0% | 4.54 | −24.9% |
| Total income | 183.44 | 176.02 | +4.2% | 186.22 | −1.5% |
| Profit before tax | 29.12 | 46.89 | −37.9% | 49.45 | −41.1% |
| Net profit for the period | 22.13 | 34.93 | −36.6% | 36.85 | −39.9% |
| EPS, basic (₹) | 13.38 | 21.12 | not comparable | 22.28 | not comparable |
| Net margin (%) | 12.3 | 20.2 | 20.3 |
Consolidated
- Filed with BSE
- 27 Jan 2026, 20:02 IST
- Board meeting
- 27 Jan 2026
- Period
- 01 Oct 2025 to 31 Dec 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 27 Jan 2026, 20:02 IST
- Board meeting
- 27 Jan 2026
- Period
- 01 Oct 2025 to 31 Dec 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE